Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663279 | 0.85 | DPP4 (0.60) | DPP4DPP7 | |
| SCHEMBL6462811 | 0.85 | DPP4 (0.60) | DPP4DPP7 | |
| SCHEMBL7573297 | 0.78 | SIGMAR1 (0.56) | — | |
| SCHEMBL3829097 | 0.78 | SIGMAR1 (0.51) | — | |
| SCHEMBL6444045 | 0.76 | DPP4 (0.54) | DPP4DPP7 | |
| SCHEMBL3827793 | 0.72 | MC4R (0.47) | — | |
| SCHEMBL3834075 | 0.72 | SIGMAR1 (0.47) | — | |
| SCHEMBL5407916 | 0.71 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL4665021 | 0.70 | DPP4 (0.72) | DPP4DPP7 | |
| SCHEMBL14102394 | 0.70 | DPP4 (0.61) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | DPP4 1/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.